CDC's Independent Advisory Committee on Immunization Practices (ACIP)

Posted about 1 year ago

CDC’s independent Advisory Committee on Immunization Practices (ACIP) recommended that people with moderately to severely compromised immune systems receive an additional dose of mRNA COVID-19 vaccine following their initial 2-dose vaccination series. CDC Director Dr. Rochelle Walensky accepted those recommendations, and released a statement .


Below is a list of resources related to the recommendation:

  1. Updated Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States

  2. New web page for consumers

  3. New web page for healthcare providers


In addition, please see here, listed under Media Talking Points, for Key Messages to help with communications around this update.


Widespread vaccination is a critical tool to help stop this pandemic. At a time when the Delta variant is surging, an additional dose could help prevent serious and possibly life-threatening COVID-19 cases within this population. It’s important to note that CDC does not recommend additional doses or booster shots for any other population at this time. Vaccine providers should administer vaccine in accordance with the updated EUAs per the COVID-19 vaccine provider agreement.


It’s important to note that individuals can self-attest and receive the additional dose wherever vaccines are offered. This will help ensure there are not additional barriers to access for this vulnerable population receiving a needed additional dose. CDC will be providing further information regarding vaccine administration to immunocompromised individuals to states, pharmacies, health centers, and all vaccine providers.


COVID-19 Vaccine Resources


  1. FDA authorizes additional dose of vaccine for immunocompromised individuals The U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. The Centers for Disease Control and Prevention  Advisory Committee on Immunization Practices met on August 13, 2021, to discuss further clinical recommendations regarding immunocompromised individuals. To learn more, please visit:  Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals | FDA

  1. COVID-19 Vaccines While Pregnant or Breastfeeding — COVID-19 vaccination is recommended for all people 12 years and older, including people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future. Evidence about the safety and effectiveness of COVID-19 vaccination during pregnancy has been growing. This data suggests that the benefits of receiving a COVID-19 vaccine outweigh any known or potential risks of vaccination during pregnancy. To learn more, please visit: COVID-19 Vaccines While Pregnant or Breastfeeding (

  1. Research Article: Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21 There is continuing public concern about the safety of COVID-19 vaccination during pregnancy. While there is no compelling biological reason to expect that mRNA COVID-19 vaccination (either preconception or during pregnancy) presents a risk to pregnancy, data are limited. It is, however, well documented that SARS-CoV-2 infection during pregnancy is associated with severe illness and increased risk of adverse pregnancy outcomes. Among recognized pregnancies in high-income countries, 1116% end in spontaneous abortion (SAB). To learn more, please visit: Research Square Article.

  1. In Case You Missed It COCA Call: Therapeutic Options to Prevent Severe COVID-19 in Immunocompromised People The Clinician Outreach and Communication Activity (COCA) held a call Thursday, August 12, 2021, from 2:00–3:00 p.m. (Eastern Time). During this COCA Call, presenters discussed the FDAs role in issuing Emergency Use Authorizations for certain monoclonal antibodies, options for compassionate use, the process for ordering and distributing monoclonal antibodies, and current data on using monoclonal antibodies for both non-hospitalized and immunocompromised patients. Presenters also covered preventing, diagnosing, and treating COVID-19 in immunocompromised patients, including the role of monoclonal antibodies, serologic testing, and potential third dose of COVID-19 vaccinations. For the recording of this call, please visit: COCA Calls/Webinars.